Isracann Biosciences Announces Delay in Filing Annual Financial Statements
Isracann Biosciences Announces Delay in Filing Annual Financial Statements
VANCOUVER, British Columbia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the "Company") announces that the filing of its audited annual financial statements for the year ended May 31, 2022, including the related management discussion and analysis, and CEO and CFO certifications (collectively, the "Annual Financial Filings") were not filed by the required filing deadline of September 28, 2022 (the "Filing Deadline"). The Annual Financial Filings are late due to unforeseen delays in the completion of the Company's audit. The unforeseen delay is due to the fact that the Company acquired operations in Israel and in Canada during the fiscal period and the auditors are trying to consolidate the audit and have lack of time to complete procedures.
不列顛哥倫比亞省溫哥華，2022年9月29日（環球新聞專線）——Isracann Biosciences Inc.（CSE：IPOT）（XFRA：A2PT0E）（場外交易代碼：ISCNF）（“公司”）宣佈，已提交截至2022年5月31日止年度的經審計的年度財務報表，包括相關的管理層討論和分析以及首席執行官和首席財務官認證（統稱爲 “年度財務申報”）未在規定的申請截止日期（2022年9月28日）（“申請截止日期”）之前提交。由於公司審計的完成出現不可預見的延遲，年度財務申報延遲。之所以出現不可預見的延誤，是因爲該公司在本財政期間收購了以色列和加拿大的業務，核數師正在努力整合審計，但沒有時間完成程序。
The Company's staff are working diligently with its auditors and the Company anticipates that it will be in a position to file the Annual Financial Filings within the next seven weeks.
該公司的員工正在努力與核數師合作，公司預計將能夠在未來七週內提交年度財務報告。
The Company has voluntarily applied to the applicable securities regulatory authorities and received a management cease trade order related to the Company's securities to be imposed the management of the Company to trade securities of the Company. The management cease trade order will be in effect until the Annual Financial Filings are filed. All other securityholders will still be able to trade in the securities of the Company in accordance with applicable securities laws.
公司已自願向適用的證券監管機構提出申請，並收到了與公司證券有關的管理停止交易令，要求公司管理層交易公司證券。在提交年度財務申報之前，管理層停止交易令將一直有效。所有其他證券持有人仍然能夠根據適用的證券法交易公司的證券。
Until the Annual Financial Filings are filed, the Company intends to provide information in accordance with National Policy 12-203 Cease Trade Orders for Continuous Disclosure Defaults.
在提交年度財務申報之前，公司打算根據國家政策12-203提供信息 因持續披露違約而停止交易訂單。
ON BEHALF OF THE BOARD OF DIRECTORS
代表董事會
"Phil Floucault"
“菲爾·弗盧科”
Phil Floucault
Chief Executive Officer and President
菲爾·弗盧科
首席執行官兼總裁
About Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)
Isracann is a multidisciplinary cannabis focused producer and product developer with Israeli-based cannabis production farm assets and a Canadian natural health medicine development and production arm. Concurrently focused on initial retail sales in Canada and in becoming a premier cannabis producer offering low-cost domestic Israeli production, the Company aims to commercialize natural health medicines in Canada and to leverage agreements within Israel for import/export opportunities and medicinal marijuana cultivation. For more information visit: .
關於 Isracann Biosciences Inc.（CSE：IPOT）（XFRA：A2PT0E）（場外交易代碼：ISCNF）
Isracann是一家專注於大麻的多學科生產商和產品開發商，擁有總部位於以色列的大麻生產農場資產和加拿大的天然健康藥物開發和生產部門。該公司同時專注於加拿大的初始零售銷售，併成爲提供低成本以色列國內生產的主要大麻生產商，其目標是在加拿大實現天然健康藥物的商業化，並利用以色列國內的協議來提供進出口機會和藥用大麻種植。欲了解更多信息，請訪問： 。
Contact
Empire Communications Group
+1 (604) 343-2724
info@isracann.com
聯繫我們
帝國通訊集團
+1 (604) 343-2724
info@isracann.com
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements may include, without limitation, statements relating to the Company's plans or goals, the Offering and the proceeds of the Offering. The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. All forward-looking statements in this press release are made as of the date of this press release. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in the Company's documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Alberta Securities Commission, and the Ontario Securities Commission. Although Isracann believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Isracann expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
前瞻性信息
本新聞稿可能包含前瞻性陳述。前瞻性陳述不是歷史事實，通常以 “期望”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛力” 和類似的表述來識別，或者事件或條件 “將”、“將”、“可能”、“可能” 或 “應該” 發生。前瞻性陳述可能包括但不限於與公司的計劃或目標、本次發行和發行收益有關的陳述。本警示聲明對本新聞稿中包含的前瞻性陳述進行了明確的全部限定。本新聞稿中的所有前瞻性陳述均自本新聞稿發佈之日起作出。此處包含的前瞻性陳述通常還受假設、風險和不確定性的約束，這些假設、風險和不確定性在公司不時向加拿大證券交易所、不列顛哥倫比亞省證券委員會、艾伯塔省證券委員會和安大略省證券委員會提交的文件中不時描述。儘管Isracann認爲此類前瞻性陳述中表達的預期是基於合理的假設，但此類陳述並不能保證未來的表現，實際業績可能與前瞻性陳述中的預期存在重大差異。無論是由於新信息、未來事件還是其他原因，Isracann明確表示不打算或義務更新或修改任何前瞻性陳述。
The CSE does not accept responsibility for the adequacy or accuracy of this release.
CSE 對本新聞稿的充分性或準確性不承擔任何責任。
譯文內容由第三人軟體翻譯。